Nucleocapsid Antigenemia in Patients Receiving Anti-CD20 Therapy With Protracted COVID-19.
Eli WilberPardis SabetiAhmed BabikerKaleb McLendonWilliam O'SickEric FittsAndrew S WebsterHans VerkerkeJames S KimVarun K PhadkeNadine G RouphaelBoghuma K TitanjiWilliam T BlakeJessica Howard-AndersonJohn D RobackWilbur A LamGregory L DamhorstPublished in: Open forum infectious diseases (2022)
Immunocompromised patients with prolonged coronavirus disease 2019 symptoms present diagnostic and therapeutic challenges. We measured viral nucleocapsid antigenemia in 3 patients treated with anti-CD20 immunotherapy who acquired severe acute respiratory syndrome coronavirus 2 infection and experienced protracted symptoms. Our results support nucleocapsid antigenemia as a marker of persistent infection and therapeutic response.